Literature DB >> 15906087

Expression of amino acid sequences of the chromogranin A molecule and synaptic vesicle protein 2 in neuroendocrine tumors of the lung.

Guida Maria Portela-Gomes1, Lars Grimelius, Mats Stridsberg, Enrica Bresaola, Giuseppe Viale, Giuseppe Pelosi.   

Abstract

Chromogranin A (CgA) and its valuable complement synaptic vesicle protein 2 (SV2) are neuroendocrine (NE) markers. Post-translational processing of CgA has been reported to vary in different NE cell types and tumors, but little is known regarding the expression of various CgA epitopes and SV2 in NE pulmonary tumors. We studied the immunoreactivity to six CgA epitopes and SV2 in ten typical (TC) and ten atypical (ACT) carcinoids, five large-cell NE carcinomas (LCNEC) and five small-cell carcinomas (SCLC), also comparing the results with clinicopathological characteristics of tumors. The sequences CgA 17--38 (vasostatin), 176--195 (chromacin), 375--384 (parastatin) and 411--424 (C-terminal parastatin) and SV2 were relevant markers for the CT/ATC group, whereas the antibody to CgA 176--195 was a better marker for the LCNEC/SCLC group. An inverse correlation was found between proliferative activity and granule-related markers in the CT/ACT group, and a direct correlation in poorly differentiated tumors. The expression of granule-related markers did not correlate with hormone content or clinical characteristics of NE tumors. The expression of CgA epitopes and SV2 occurs in all NE tumors, differing between better differentiated and poorly differentiated tumors but not within the respective groups.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15906087     DOI: 10.1007/s00428-005-1222-6

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  27 in total

1.  Synaptic vesicle protein 2, A new neuroendocrine cell marker.

Authors:  G M Portela-Gomes; A Lukinius; L Grimelius
Journal:  Am J Pathol       Date:  2000-10       Impact factor: 4.307

Review 2.  Revised classification of neuroendocrine tumours of the lung, pancreas and gut.

Authors:  C Capella; P U Heitz; H Höfler; E Solcia; G Klöppel
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

3.  Decreased survival in patients with CD44-negative typical bronchial carcinoid tumors.

Authors:  D Granberg; E Wilander; K Oberg; B Skogseid
Journal:  Int J Cancer       Date:  1999-10-22       Impact factor: 7.396

4.  Chromogranin A in human neuroendocrine tumors: an immunohistochemical study with region-specific antibodies.

Authors:  G M Portel-Gomes; L Grimelius; H Johansson; E Wilander; M Stridsberg
Journal:  Am J Surg Pathol       Date:  2001-10       Impact factor: 6.394

5.  Ultrastructural localization of chromogranin: a potential marker for the electron microscopical recognition of endocrine cell secretory granules.

Authors:  I M Varndell; R V Lloyd; B S Wilson; J M Polak
Journal:  Histochem J       Date:  1985-09

Review 6.  Regulation of endothelial cell shape and barrier function by chromogranin A.

Authors:  E Ferrero; E Magni; F Curnis; A Villa; M E Ferrero; A Corti
Journal:  Ann N Y Acad Sci       Date:  2002-10       Impact factor: 5.691

7.  Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid.

Authors:  W D Travis; W Rush; D B Flieder; R Falk; M V Fleming; A A Gal; M N Koss
Journal:  Am J Surg Pathol       Date:  1998-08       Impact factor: 6.394

8.  Independent value of fascin immunoreactivity for predicting lymph node metastases in typical and atypical pulmonary carcinoids.

Authors:  Giuseppe Pelosi; Felice Pasini; Filippo Fraggetta; Ugo Pastorino; Antonio Iannucci; Patrick Maisonneuve; Gianluigi Arrigoni; Giovanni De Manzoni; Enrica Bresaola; Giuseppe Viale
Journal:  Lung Cancer       Date:  2003-11       Impact factor: 5.705

Review 9.  TNM classification for lung cancer.

Authors:  Yoh Watanabe
Journal:  Ann Thorac Cardiovasc Surg       Date:  2003-12       Impact factor: 1.520

10.  Vasoinhibitory activity of synthetic peptides from the amino terminus of chromogranin A.

Authors:  R H Angeletti; S Aardal; G Serck-Hanssen; P Gee; K B Helle
Journal:  Acta Physiol Scand       Date:  1994-09
View more
  3 in total

Review 1.  Immunohistochemical and biochemical studies with region-specific antibodies to chromogranins A and B and secretogranins II and III in neuroendocrine tumors.

Authors:  Guida M Portela-Gomes; Lars Grimelius; Mats Stridsberg
Journal:  Cell Mol Neurobiol       Date:  2010-11-03       Impact factor: 5.046

2.  Chromogranin A in gastric neuroendocrine tumours: an immunohistochemical and biochemical study with region-specific antibodies.

Authors:  Andreas Tartaglia; Guida M Portela-Gomes; Kjell Oberg; Paolo Vezzadini; Maria P Foschini; Mats Stridsberg
Journal:  Virchows Arch       Date:  2006-01-12       Impact factor: 4.064

3.  Biological function and clinical relevance of chromogranin A and derived peptides.

Authors:  Maria Angela D'amico; Barbara Ghinassi; Pascal Izzicupo; Lamberto Manzoli; A Di Baldassarre
Journal:  Endocr Connect       Date:  2014-04-29       Impact factor: 3.335

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.